HLA and pharmacogenetics of drug hypersensitivity.
暂无分享,去创建一个
[1] Yi-wu Shi,et al. Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. , 2011, Basic & clinical pharmacology & toxicology.
[2] K. Boki,et al. HLA-A,-B, and -DR antigens in relation to gold and D-penicillamine toxicity in Greek patients with RA. , 1986, Disease markers.
[3] L. K. Ely,et al. Natural HLA Class I Polymorphism Controls the Pathway of Antigen Presentation and Susceptibility to Viral Evasion , 2004, The Journal of experimental medicine.
[4] M. Tohyama,et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug‐induced hypersensitivity syndrome , 2007, The British journal of dermatology.
[5] Shui-Tein Chen,et al. HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. , 2007, The Journal of allergy and clinical immunology.
[6] S. Mallal,et al. HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity , 2014, AIDS.
[7] C. Sotozono,et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2008, Pharmacogenomics.
[8] S. Chan,et al. HLA and allopurinol drug eruption. , 1989, Dermatologica.
[9] I. Cascorbi,et al. Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens , 2007, The Pharmacogenomics Journal.
[10] R. Hui,et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. , 2010, Pharmacogenomics.
[11] Jacqueline Adam,et al. Avidity determines T‐cell reactivity in abacavir hypersensitivity , 2012, European journal of immunology.
[12] V. Soriano,et al. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701. , 2010, The Journal of antimicrobial chemotherapy.
[13] Chen-Yang Shen,et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.
[14] M. Martinetti,et al. Tag SNPs of the ancestral haplotype 57.1 do not substitute HLA-B*57:01 typing for eligibility to abacavir treatment in the Italian population. , 2012, Pharmacogenomics.
[15] J. Lieberman,et al. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. , 1990, Archives of general psychiatry.
[16] Yusuke Nakamura,et al. Genome-wide association study identifies HLA-A ∗ 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population , 2022 .
[17] J. Stern,et al. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. , 2001, The AIDS reader.
[18] R. Walensky,et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV , 2008, AIDS.
[19] W. Pichler,et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. , 1997, The Journal of clinical investigation.
[20] K. Tokunaga,et al. Tumor necrosis factor α 5'-flanking region, tumor necrosis factor receptor II, and HLA-DRB1 polymorphisms in Japanese patients with rheumatoid arthritis , 2000 .
[21] M. Pirmohamed,et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. , 2003, Molecular pharmacology.
[22] N. Chaiyakunapruk,et al. Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis , 2011, BMC Medical Genetics.
[23] M. Pirmohamed,et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. , 2004, Pharmacogenetics.
[24] C. Sotozono,et al. HLA‐B*1511 is a risk factor for carbamazepine‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in Japanese patients , 2010, Epilepsia.
[25] E. Phillips,et al. A review of drug patch testing and implications for HIV clinicians , 2008, AIDS.
[26] T. Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing , 2012, Clinical pharmacology and therapeutics.
[27] Abraham Weizman,et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. , 1998, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.
[28] Hsin-Yun Sun,et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. , 2007, The Journal of antimicrobial chemotherapy.
[29] S. Mallal,et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] T. Shiohara,et al. Drug-induced Hypersensitivity Syndrome(DIHS): A Reaction Induced by a Complex Interplay among Herpesviruses and Antiviral and Antidrug Immune Responses. , 2006, Allergology international : official journal of the Japanese Society of Allergology.
[31] J. Roujeau,et al. Genetic susceptibility to toxic epidermal necrolysis. , 1987, Archives of dermatology.
[32] C. Moore,et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.
[33] C. Sempoux,et al. HLA association of amoxicillin-clavulanate--induced hepatitis. , 1999, Gastroenterology.
[34] J. Jung,et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans , 2011, Pharmacogenetics and genomics.
[35] J Rossjohn,et al. Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. , 2011, Tissue antigens.
[36] Yusuke Nakamura,et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] J. González-Domínguez,et al. Association of HLA-DR5 with mucocutaneous lesions in patients with rheumatoid arthritis receiving gold sodium thiomalate. , 1994, The Journal of rheumatology.
[38] H. Yazaki,et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. , 2007, AIDS.
[39] Yusuke Nakamura,et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients , 2009, Pharmacogenetics and genomics.
[40] J. Fernández-López,et al. Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos. , 2011, Pharmacogenomics.
[41] C. Kemper,et al. Frequency of Cutaneous Reactions on Rechallenge with Nevirapine and Delavirdine , 2000, The Annals of pharmacotherapy.
[42] D. Beltramo,et al. Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir. , 2011, Clinica chimica acta; international journal of clinical chemistry.
[43] K. Welsh,et al. Influence of MHC CLASS II in Susceptibility to Beryllium Sensitization and Chronic Beryllium Disease 1 , 2003, The Journal of Immunology.
[44] K. Williams,et al. Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? , 2012, Internal medicine journal.
[45] E. Autret‐Leca,et al. Strontium ranelate‐induced DRESS syndrome: first two case reports , 2009, Allergy.
[46] G. Hur,et al. Pharmacogenetics of aspirin-intolerant asthma. , 2008, Pharmacogenomics.
[47] M. Muramatsu,et al. HLA Class I markers in Japanese patients with carbamazepine‐induced cutaneous adverse reactions , 2010, Epilepsia.
[48] H. Merk,et al. Delayed-type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific αβ+ human T-cell clones , 2002 .
[49] A. Romano,et al. Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[50] M. Daly,et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. , 2011, Gastroenterology.
[51] S. Mallal,et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire , 2012, Proceedings of the National Academy of Sciences.
[52] Dong Zhou,et al. Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population , 2010, Epilepsy Research.
[53] S. Tiamkao,et al. HLA‐B*1502 Strongly Predicts Carbamazepine‐Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Thai Patients with Neuropathic Pain , 2012, Pain practice : the official journal of World Institute of Pain.
[54] C. Suh,et al. The human leucocyte antigen‐DRB1*1302‐DQB1*0609‐DPB1*0201 haplotype may be a strong genetic marker for aspirin‐induced urticaria , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[55] C. Dollery,et al. HYDRALAZINE-INDUCED SYSTEMIC LUPUS ERYTHEMATOSUS: INFLUENCE OF HLA-DR AND SEX ON SUSCEPTIBILITY , 1980, The Lancet.
[56] T. Kakamu,et al. HLA‐A31 strongly associates with carbamazepine‐induced adverse drug reactions but not with carbamazepine‐induced lymphocyte proliferation in a Japanese population , 2012, The Journal of dermatology.
[57] D. Nolan. HLA-B*5701 screening prior to abacavir prescription: Clinical and laboratory aspects , 2009, Critical reviews in clinical laboratory sciences.
[58] R. Queiro-Silva,et al. BAT1 promoter polymorphism is associated with rheumatoid arthritis susceptibility. , 2008, Journal of Rheumatology.
[59] B. K. Park,et al. Immune pathomechanism of drug hypersensitivity reactions. , 2011, The Journal of allergy and clinical immunology.
[60] S. Mallal,et al. HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. , 2005, Tissue antigens.
[61] S. Mallal,et al. External Quality Assessment of HLA-B*5701 Reporting: An International Multicentre Survey , 2007, Antiviral therapy.
[62] B. Dong,et al. HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients. , 2012, AIDS research and human retroviruses.
[63] A. Cutrell,et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir , 2004, The Annals of pharmacotherapy.
[64] P. Kwan,et al. Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese , 2007, Epilepsia.
[65] J. Reginster,et al. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity , 2010, Osteoporosis International.
[66] R. N. Macsween,et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association , 2000, Gut.
[67] K. Cao,et al. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. , 2001, Human immunology.
[68] S. Jee,et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.
[69] A. Hovnanian,et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz , 2008, AIDS.
[70] C. Sotozono,et al. A whole-genome association study of major determinants for allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients , 2011, The Pharmacogenomics Journal.
[71] A. Malhotra,et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. , 2011, The Journal of clinical psychiatry.
[72] C. Moore,et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts , 2005, AIDS.
[73] T. Carrillo,et al. Association of HLA-DR11 with the anaphylactoid reaction caused by nonsteroidal anti-inflammatory drugs. , 1999, The Journal of allergy and clinical immunology.
[74] K. Suphapeetiporn,et al. Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population , 2008, Epilepsia.
[75] D. Podzamczer,et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent , 2011, AIDS.
[76] S. Hetherington,et al. Risk factor analysis of hypersensitivity reactions to abacavir. , 2002, Clinical therapeutics.
[77] A. Urbańska,et al. Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV‐infected patients , 2010, HIV medicine.
[78] Yuan-Tsong Chen,et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. , 2011, The Journal of allergy and clinical immunology.
[79] N. Frahm,et al. Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles , 2011, PLoS pathogens.
[80] K. Squires,et al. Increased HIV infection rate among violent deaths: a mortuary study in the Republic of Congo , 2008, AIDS (London).
[81] W. Pichler,et al. Pathogenesis of drug‐induced exanthems , 2002, Allergy.
[82] J. McCluskey,et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. , 2012, Annual review of pharmacology and toxicology.
[83] M. Pirmohamed,et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism‐dependent haptenation and T‐cell proliferation in vivo , 2001, British journal of pharmacology.
[84] T. Shiohara,et al. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. , 2009, Immunology and allergy clinics of North America.
[85] C. Carcassi,et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients , 2006, AIDS.
[86] S. Tiamkao,et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population , 2009, Pharmacogenetics and genomics.
[87] K. King,et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] C. Joshi,et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. , 2009, Indian journal of dermatology, venereology and leprology.
[89] I. James,et al. Cytokine Profiling in Abacavir Hypersensitivity Patients , 2008, Antiviral therapy.
[90] D. Margulies,et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01 an autoimmune model for HLA-associated drug hypersensitivity , 2012, AIDS.
[91] L. Calza,et al. Safety issues about nevirapine administration in HIV-infected pregnant women. , 2007, Journal of acquired immune deficiency syndromes.
[92] R. Pollard,et al. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. , 1998, Clinical therapeutics.
[93] Q. Wang,et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland , 2011, Seizure.
[94] A. Daly,et al. Flucloxacillin-induced liver injury. , 2008, Toxicology.
[95] C. Yeung,et al. Association between HLA‐B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong , 2012, The British journal of dermatology.
[96] W. Pichler,et al. Allele-unrestricted presentation of lidocaine by HLA-DR molecules to specific alphabeta+ T cell clones. , 1998, International immunology.
[97] B. Thiers. HLA-B*5801 Allele as a Genetic Marker for Severe Cutaneous Adverse Reactions Caused by Allopurinol , 2006 .
[98] Réjean Thomas,et al. Switch From Enfuvirtide to Raltegravir in Patients With Undetectable Viral Load: Efficacy and Safety at 24 Weeks in a Montreal Cohort , 2009, Journal of acquired immune deficiency syndromes.
[99] J. Kere,et al. The CCHCR1 (HCR) gene is relevant for skin steroidogenesis and downregulated in cultured psoriatic keratinocytes , 2007, Journal of Molecular Medicine.
[100] M. Nelson,et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients , 2009, Pharmacogenetics and genomics.
[101] J. McCluskey,et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire , 2012, Nature.
[102] Hye‐Ryun Kang,et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. , 2010, Pharmacogenomics.
[103] David Nolan,et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. , 2008, Immunity.
[104] B. Taiwo,et al. Nevirapine toxicity. , 2006, International journal of STD & AIDS.
[105] S. Tiamkao,et al. Association between HLA‐B*1502 and carbamazepine‐induced severe cutaneous adverse drug reactions in a Thai population , 2010, Epilepsia.
[106] B. K. Park,et al. Metabolic and chemical origins of cross-reactive immunological reactions to arylamine benzenesulfonamides: T-cell responses to hydroxylamine and nitroso derivatives. , 2010, Chemical research in toxicology.
[107] H. Stefan,et al. Phenytoin-induced Stevens–Johnson syndrome with negative HLA-B*1502 allele in mainland China: Two cases , 2011, Seizure.
[108] Jacques Fellay,et al. A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1 , 2007, Science.
[109] Clive E. Bowman,et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.
[110] J. Nishikawa,et al. Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLA-B*58:01: a partially predictive but useful biomarker for allopurinol-related Stevens-Johnson syndrome/toxic epidermal necrolysis in Japanese. , 2012, Drug metabolism and pharmacokinetics.
[111] Martin Schumacher,et al. Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe , 2011, Orphanet journal of rare diseases.
[112] P. Sarzi-Puttini,et al. RETRACTED: Drug-induced lupus erythematosus , 2005, Autoimmunity.
[113] V. Hertzberg,et al. HLA class II DPB1 and DRB1 polymorphisms associated with genetic susceptibility to beryllium toxicity , 2010, Occupational and Environmental Medicine.
[114] J. Vandenbroucke,et al. HLA associations in aurothioglucose- and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis. , 2008, Tissue antigens.
[115] K. Shianna,et al. Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. , 2012, Pharmacogenomics.
[116] S. Murad,et al. Association of HLA‐B*1502 allele with carbamazepine‐induced toxic epidermal necrolysis and Stevens–Johnson syndrome in the multi‐ethnic Malaysian population , 2011, International journal of dermatology.
[117] W. Miller,et al. Sex differences in nevirapine rash. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[118] S. Mallal,et al. Refining Abacavir Hypersensitivity Diagnoses using a Structured Clinical Assessment and Genetic Testing in the Swiss HIV Cohort Study , 2008, Antiviral therapy.
[119] M. Pirmohamed,et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. , 2006, Pharmacogenomics.
[120] J. Stockman. HLA-A∗3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans , 2012 .
[121] S. Caillat-Zucman,et al. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. , 2007, Journal of acquired immune deficiency syndromes.
[122] R. Jamal,et al. Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. , 2011, Asian Pacific journal of allergy and immunology.
[123] F. T. P. Group,et al. Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens , 2007, Drug safety.
[124] G. Aithal,et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. , 2007, Gastroenterology.
[125] R. A. Diez. HLA-B27 and agranulocytosis by levamisole. , 1990, Immunology today.
[126] J. Kere,et al. The PSORS1 locus gene CCHCR1 affects keratinocyte proliferation in transgenic mice. , 2007, Human molecular genetics.
[127] D. Roden,et al. The Phenotype Standardization Project: Improving Pharmacogenetic Studies of Serious Adverse Drug Reactions , 2011, Clinical pharmacology and therapeutics.
[128] R. Cairoli,et al. A study of HLA class I and class II 4‐digit allele level in Stevens–Johnson syndrome and toxic epidermal necrolysis , 2011, International journal of immunogenetics.
[129] K. Tokunaga,et al. Tumor necrosis factor alpha 5'-flanking region, tumor necrosis factor receptor II, and HLA-DRB1 polymorphisms in Japanese patients with rheumatoid arthritis. , 2000, Arthritis and rheumatism.
[130] A. Roses,et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. , 2004, Pharmacogenomics.
[131] M. Daly,et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.
[132] S. Knowles,et al. Anticonvulsant Hypersensitivity Syndrome , 1999, Drug safety.
[133] Sheau-Fang Yang,et al. Oxcarbazepine‐induced Stevens‐Johnson Syndrome: A Case Report , 2009, The Kaohsiung journal of medical sciences.
[134] G. Gandhi,et al. Psoriasis-Associated Genetic Polymorphism in North Indian Population in the CCHCR1 Gene and in a Genomic Segment Flanking the HLA-C Region , 2011, Disease markers.
[135] Elizabeth J Phillips,et al. HLA-B*1502 screening and toxic effects of carbamazepine. , 2011, The New England journal of medicine.
[136] J. Gill,et al. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta. , 2012, Human immunology.
[137] Limei Zhao,et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients , 2011, European Journal of Clinical Pharmacology.
[138] R. Paredes,et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. , 2006, AIDS research and human retroviruses.
[139] Yuan-Tsong Chen,et al. A marker for Stevens–Johnson syndrome , 2004 .
[140] J. Kelsoe,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Carbamazepine Dosing , 2012, Clinical pharmacology and therapeutics.
[141] S. Mallal,et al. Pharmacogenetics of drug hypersensitivity. , 2010, Pharmacogenomics.
[142] V. Soriano,et al. Liver toxicity caused by nevirapine. , 2002, AIDS.
[143] M. Pirmohamed,et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. , 2003, The Journal of allergy and clinical immunology.
[144] S. Knowles,et al. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. , 2002, AIDS.
[145] Yao Ju,et al. HLA-B~*5701 screening for hypersensitivity to abacavir , 2011 .
[146] S. Mallal,et al. HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay. , 2007, Tissue antigens.
[147] V. Shotelersuk,et al. Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions , 2011, Journal of Clinical Neuroscience.
[148] P. G. Choe,et al. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[149] E. Wolf,et al. Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany , 2010, European journal of medical research.
[150] P. Kwan,et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China , 2010, Epilepsy & Behavior.
[151] Jacques Fellay,et al. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. , 2008, The Journal of infectious diseases.
[152] M. Pirmohamed,et al. Activation of T cells by carbamazepine and carbamazepine metabolites. , 2006, The Journal of allergy and clinical immunology.
[153] C. Day,et al. Genetic association studies in drug-induced liver injury. , 2009, Seminars in liver disease.
[154] W. Prasithsirikul,et al. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients , 2009, AIDS research and therapy.
[155] Yuan-Tsong Chen,et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. , 2012, The Journal of allergy and clinical immunology.
[156] M. Youle,et al. Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population , 2009, HIV medicine.
[157] J. Jung,et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[158] Howard L McLeod,et al. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. , 2008, Pharmacogenomics.
[159] R. Pellicano,et al. Genetic susceptibility to fixed drug eruption: evidence for a link with HLA-B22. , 1994, Journal of American Academy of Dermatology.
[160] P. Gasparini,et al. Fixed drug eruptions with feprazone are linked to HLA-B22. , 1997, Journal of the American Academy of Dermatology.
[161] L. Naldi,et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.
[162] P. Peters,et al. Nevirapine‐associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya , 2010, HIV medicine.
[163] S. Lewitzky,et al. OC-035 Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a diagnostic test accuracy meta-analysis , 2010, Gut.
[164] U. Akar,et al. Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. , 2001, Journal of the American Academy of Dermatology.
[165] M. Schumacher,et al. A marker for Stevens-Johnson syndrome …: ethnicity matters , 2006, The Pharmacogenomics Journal.
[166] A Jawaid,et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis , 2008, The Pharmacogenomics Journal.
[167] H. Uchi,et al. Stevens-Johnson Syndrome, Drug-Induced Hypersensitivity Syndrome and Toxic Epidermal Necrolysis Caused by Allopurinol in Patients with a Common HLA Allele: What Causes the Diversity? , 2007, Dermatology.
[168] C. Hsiao,et al. Oxcarbazepine‐induced Stevens–Johnson syndrome in a patient with HLA‐B*1502 genotype , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.
[169] W. Pichler,et al. T cell recognition of penicillin G: Structural features determining antigenic specificity , 1996, European journal of immunology.
[170] I. James,et al. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients , 2007, AIDS.
[171] V. Paradis,et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. , 2009, Archives of dermatology.
[172] M. Marcilla,et al. B*2707 differs in peptide specificity from B*2705 and B*2704 as much as from HLA‐B27 subtypes not associated to spondyloarthritis , 2006, European journal of immunology.
[173] Sang-Heon Cho,et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans , 2011, Epilepsy Research.